证券代码：002653 证券简称：海思科 公告编号：2023-110 海思科医药集团股份有限公司 关于收购控股子公司股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、交易概述 海思科医药集团股份有限公司（以下简称"公司"或"海思科"） 全资孙公司Haisco Holdings PTE.LTD.（以下简称"海思科控股"）持 有Haisco Pharmaceutical Holdings Group Limited（以下简称"海 思科药业控股集团"）80%股权，海思科药业控股集团持有HAISCO PHARMACEUTICALS PTE.LTD.（以下简称"新加坡药业"）100%股权。 基于公司发展规划，公司三级全资子公司Haisco Holdings Group Limited（以下简称"海思科控股集团"）拟以自有资金共计228.11万 美元收购海思科药业控股集团持有的新加坡药业100%股权。 股权架构图如下： 1 注册地：开曼 地址：Sertus Chambers, Governors Square, Suite # 5-204, 23 Lime ...

证券代码：002653 证券简称：海思科 公告编号：2023-111 海思科医药集团股份有限公司 公司三级全资子公司 Haisco Holdings Group Limited（以下简 称"海思科控股集团"）以自有资金共计 7,422.43 万美元收购 Haisco Pharmaceutical Holdings Group Limited（以下简称"海思科药业 控股集团"）持有的 Haisco-USA Pharmaceuticals,Inc.（以下简称 "美国海思科"）100%股权和 Haisco Innovative Pharmaceutical PTE. LTD.（以下简称"新加坡创新药公司"）100%股权，其中：美国海思 科股权受让价款为 1,882.04 万美元，新加坡创新药公司股权受让价 款为 5,540.39 万美元。 具体内容详见公司于 2023 年 3 月 4 日披露于巨潮资讯网等媒体 上的《关于收购控股子公司股权的公告》（公告编号：2023-028）。 二、进展情况 1 2023 年 3 月 27 日，海思科控股集团与海思科药业控股集团签订 了《股权转让协议》。近日，海思科控股集团已向海思 ...

具体内容详见公司于 2023 年 7 月 26 日披露于巨潮资讯网等媒体 上的《关于对控股子公司减资暨关联交易的公告》（公告编号： 2023-082）。 1 二、进展情况 证券代码：002653 证券简称：海思科 公告编号：2023-112 海思科医药集团股份有限公司 关于对控股子公司减资暨关联交易的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、事项概述 海思科医药集团股份有限公司（以下简称"公司"）于 2023 年 7 月 26 日召开的第四届董事会第五十二次会议审议通过了《关于对 控股子公司减资暨关联交易的议案》，并经 2023 年 8 月 25 日召开的 2023 年第二次临时股东大会审议通过，关联董事王俊民先生、范秀 莲女士、郑伟先生回避表决。 海思科医药集团股份有限公司（以下简称"公司"或"海思科"） 全资孙公司 Haisco Holdings PTE.LTD.（以下简称"海思科控股"） 持有 Haisco Pharmaceutical Holdings Group Limited（以下简称 "海思科药业控股集团"）80%股权，公司关 ...

北京市中伦（深圳）律师事务所 关于海思科医药集团股份有限公司 2023 年第二次临时股东大会的 法律意见书 二〇二三年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 广东省深圳市福田区益田路 6003 号荣超中心 A 栋 8-10 层 邮编：518026 8-10/F, Tower A, Rongchao Tower, 6003 Yitian Road, Futian District, Shenzhen, Guangdong 518026, P.R. China 电话/Tel : +86 75 ...

1、现场会议召开时间：2023 年 8 月 25 日 14:00 开始 2、现场会议召开地点：四川海思科制药有限公司办公楼三楼会 议室。 证券代码：002653 证券简称：海思科 公告编号：2023-106 海思科医药集团股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 本次股东大会无增加、变更、否决提案的情况。 一、会议的召开和出席情况 3、会议召开方式：现场表决与网络投票相结合的方式。 其中通过深圳证券交易所交易系统进行网络投票的时间为 2023 年 8 月 25 日上午 9:15—9:25，9:30—11:30，下午 13:00—15:00； 通过互联网投票系统投票的时间为：2023 年 8 月 25 日 9:15 至 15:00 期间的任意时间。 4、召集人：海思科医药集团股份有限公司董事会 5、主持人：董事长王俊民先生 6、本次股东大会会议的召集、召开与表决程序符合《公司法》、 《上市公司股东大会规则》、《深圳证券交易所股票上市规则》等法律、 法规及规范性文件和《公司章程》的规定。 ...

下： | | | | | 合计占 | 合计占 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股 | | | | | | | | | | | 数量 | 持股 | 累计质押数 | 其所持 | 公司总 | 已质押股 | 占已 | 未质押股 | 占未 | | 名称 | | 比例 | 量（万股） | 股份比 | 股本比 | | | | | | | （万股） | | | | | 份限售和 | 质押 | 份限售和 | 质押 | | | | | | 例 | 例 | 冻结数量 | 股份 | 冻结数量 | 股份 | | | | | | | | （万股） | 比例 | （万股） | 比例 | 1 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次解除质 押数量 (万股) 占其所 持股份 比例 占公司总 股本比例 起始日 解除日期 解除原因 质权人 范秀莲 是 1,027 4.60% 0.92% 2020年10 月 29 日 2023 年 8 月 17 日 到期解除 质押 ...

证券代码：002653 证券简称：海思科 公告编号：2023-104 海思科医药集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日接到 公司控股股东及实际控制人之一范秀莲女士的通知，获悉范秀莲女士 所持有本公司的部分股份被质押，具体事项如下： 二、股东股份累计质押的情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如 下： | | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 持股 | | 本次质押前 | 本次质押后 | 占其所 | 占公司 | | | | | | 股东 | | 持股 | | | | | 已质押股 | 占已 | 未质押股 | 占未 | | | 数量 | | 质押股份数 | 质押股份数 | 持股份 | 总股本 | | | | | | 名称 | | 比例 | | | | | ...

Financial Performance - Revenue for the reporting period was RMB 1,369,698,088.21, a year-on-year increase of 9.81%[13] - Net profit attributable to shareholders of the listed company was RMB 75,075,253.96, a year-on-year increase of 7.52%[13] - Net cash flow from operating activities was RMB 55,296,303.29, a significant increase of 202.64% compared to the same period last year[13] - Total assets at the end of the reporting period were RMB 6,411,183,425.32, an increase of 6.01% compared to the end of the previous year[13] - Net assets attributable to shareholders of the listed company were RMB 3,971,327,318.19, a year-on-year increase of 30.83%[13] - Basic earnings per share were RMB 0.0679, an increase of 4.62% compared to the same period last year[13] - Weighted average return on equity was 1.99%, a decrease of 0.42 percentage points compared to the same period last year[13] - Revenue for the first half of 2023 reached 1.37 billion yuan, a year-on-year increase of 9.81%[25] - Total operating revenue for the first half of 2023 reached 1,369,698,088.21 yuan, a 9.8% increase compared to 1,247,346,556.30 yuan in the same period last year[156] - Net profit attributable to the parent company's shareholders was 75,075,253.96 yuan, up 7.5% from 69,822,217.46 yuan in the first half of 2022[158] - Net profit for the first half of 2023 was RMB 142,118,726.69, a significant increase compared to RMB 84,426,517.16 in the same period last year[160] - Operating cash flow for the first half of 2023 was RMB 55,296,303.29, a positive turnaround from a negative RMB 53,873,397.17 in the same period last year[162] - Sales revenue from goods and services in the first half of 2023 was RMB 1,632,546,550.25, up from RMB 1,281,113,171.35 in the same period last year[162] - Investment cash outflow for the first half of 2023 was RMB 397,907,096.19, slightly higher than RMB 387,247,396.17 in the same period last year[163] - Financing cash inflow for the first half of 2023 was RMB 1,299,101,640.51, a decrease from RMB 1,485,482,318.96 in the same period last year[163] - Cash and cash equivalents at the end of the first half of 2023 were RMB 1,193,484,371.25, up from RMB 1,056,687,105.83 at the end of the same period last year[163] - Interest expenses for the first half of 2023 were RMB 18,782,291.93, compared to RMB 13,092,338.72 in the same period last year[160] - Credit impairment loss for the first half of 2023 was RMB -20,806,273.30, a significant increase compared to RMB -2,252,100.18 in the same period last year[160] - Total comprehensive income for the first half of 2023 was RMB 136,700,749.54, down from RMB 210,212,732.83 in the same period last year[161] - The company received RMB 793,640,000.00 from equity financing in the first half of 2023, a substantial increase compared to RMB 300,817.80 in the same period last year[163] - Operating cash flow from sales of goods and services increased to 1,618,967,826.94 yuan in H1 2023, up 26.1% from 1,283,709,993.50 yuan in H1 2022[164] - Net cash flow from operating activities improved to -306,269,605.97 yuan in H1 2023, compared to -334,444,146.29 yuan in H1 2022[164] - Net cash flow from investing activities turned positive at 31,325,828.08 yuan in H1 2023, a significant improvement from -109,751,211.74 yuan in H1 2022[165] - Net cash flow from financing activities increased to 741,048,893.76 yuan in H1 2023, up 23% from 602,764,291.94 yuan in H1 2022[165] - Cash and cash equivalents at the end of H1 2023 stood at 579,380,273.70 yuan, a 70.8% increase from 339,115,976.39 yuan at the end of H1 2022[165] - Total equity attributable to owners of the parent company increased to 3,035,744,121.70 yuan in H1 2023, up from 2,997,233,240.09 yuan at the end of 2022[166] - Comprehensive income for H1 2023 was 147,921,098.39 yuan, compared to 147,623,486.24 yuan in H1 2022[167] - Capital raised from owners' investments in H1 2023 totaled 795,306,691.83 yuan, including 790,866,217.57 yuan from issuance of ordinary shares[167] - Other comprehensive income transferred to retained earnings decreased by 52,576,578.37 yuan[168] - Special reserve for the period amounted to 5,200,758.65 yuan[168] - Extraction of special reserve for the period was 7,533,880.17 yuan[168] - Usage of special reserve for the period was 2,333,121.52 yuan[168] - Other items resulted in a decrease of 12,683,667.11 yuan[168] - Total comprehensive income for the period was 111,223,289.03 yuan[170] - Owner's equity decreased by 1,078,750.00 yuan due to capital reduction[170] - Profit distribution resulted in a decrease of 214,568,345.67 yuan[170] - Special reserve for the period amounted to 2,629,665.77 yuan[171] - Extraction of special reserve for the period was 3,423,566.96 yuan[171] - The company's total owner's equity at the end of the period was 4,151,867,526.77 yuan, an increase of 982,159,382.94 yuan compared to the beginning of the period[172] - Comprehensive income for the period was 199,536,358.21 yuan, with net profit attributable to owners of 142,118,726.69 yuan[172] - Capital reserve increased by 748,633,731.84 yuan, mainly due to the issuance of new shares[172] - Undistributed profits increased by 187,255,474.09 yuan, reflecting the company's profitability[172] - The company issued 40,000,000 new shares, raising 790,866,217.58 yuan[172] - Share-based payment expenses amounted to 4,440,474.26 yuan[172] - Other comprehensive income decreased by 5,417,977.15 yuan, mainly due to changes in fair value of financial assets[172] - The company's total owner's equity at the beginning of the period was 3,169,708,143.83 yuan[172] - The company's share capital increased by 38,510,500.00 yuan due to the issuance of new shares[172] - The company's capital reserve at the beginning of the period was 56,011,510.69 yuan[172] R&D and Innovation - R&D investment in the first half of 2023 was 372 million yuan, a year-on-year increase of 7.25%, accounting for 27.15% of revenue[25] - The company's self-developed 1.1 class innovative intravenous anesthetic, ciprofol injection, has been approved in China and is in the top 3 in the domestic market[23] - The company's diabetes peripheral neuropathy drug HSK16149 and type 2 diabetes treatment drug HSK7653 have submitted NDAs and are under review[24] - The company's innovative drug HSK3486 (ciprofol injection) is undergoing phase III clinical trials in the US and is expected to be launched in the US within the next 2 years[24] - The company's clinical trials are conducted in accordance with international standards, with self-built clinical and operational teams ensuring compliance and data quality[19] - The company's innovative drugs HSK16149 and HSK7653 were presented at the ADA global diabetes conference, receiving international recognition[22] - The company has 44 R&D projects in progress, including 23 innovative drugs (19 Class 1, 3 Class 2, and 1 Class 5.1), 20 generic drugs, and 1 medical device, covering 4 therapeutic areas[26] - In the first half of 2023, the company filed 154 patent applications, with 20 granted, and applied for 4 new trademarks, with 31 approved[26] - The company's HSK31679 tablet received a clinical approval for non-alcoholic steatohepatitis in June 2023[27] - HSK38008 oral formulation received clinical approval for prostate cancer in April 2023[27] - HSK40118 tablet received clinical approval for advanced non-small cell lung cancer in March 2023[27] - The company's HSK3486 (anesthetic induction) achieved the primary endpoint in its first US Phase III trial, with a second Phase III trial ongoing and a third planned for 2023 in the US and Europe[29] - The company's HSK7653 (long-acting hypoglycemic drug) submitted an NDA in January 2023, currently under review[29] - HSK21542 (postoperative analgesia) recently submitted an NDA, with Phase III trials for chronic kidney disease pruritus progressing well[29] - The company plans to advance 2-3 innovative drugs to IND application in the second half of 2023, focusing on oncology and analgesia[36] - The company aims to initiate 3-5 new projects in the second half of 2023 to expand its product pipeline[36] - HSK7653, a treatment for type 2 diabetes, has submitted an NDA application and is in preparation for market launch[35] - HSK16149, a treatment for diabetic peripheral neuropathy, has submitted an NDA application and is preparing for market launch, with its indication for postherpetic neuralgia completing Phase III trials and preparing for NDA submission[35] - HSK21542, a postoperative analgesic, has recently submitted an NDA application, and its tablet form has completed IND application and is expected to receive clinical approval soon[35] - HSK34890, a treatment for type 2 diabetes, submitted an IND application in May 2023 and received clinical trial approval in August 2023[35] - HSK29116, a treatment for refractory B-cell lymphoma, HSK40118 for advanced non-small cell lung cancer, and HSK38008 for prostate cancer are all in Phase I clinical trials[35] - HSK31858, a treatment for non-cystic bronchiectasis, is advancing Phase II clinical trials, while HL231 for COPD has completed Phase II and is preparing for Phase III trials[35] - The company has 777 Chinese patents, 35 US patents, and 171 PCT patents, with 198 Chinese patents and 12 US patents already granted[40] - The company has established a comprehensive technology system from early drug discovery to commercialization, including platforms like Protac and PDC, which enhance drug development efficiency[39] - R&D expenses increased to 209,474,983.33 yuan, a 16.2% rise compared to 180,216,180.53 yuan in the first half of 2022[157] - The company has undertaken 6 national-level research projects as of June 30, 2023[44] - The company has published nearly 40 papers in core journals, focusing on anesthesia, analgesia, and diabetes[44] - The R&D team consists of over 800 personnel, with 39% holding master's degrees or higher[45] - The chemical team includes over 100 researchers, with 73% holding master's degrees or higher[46] - The biological team has developed multiple international innovation platforms, including target validation and screening platforms[46] - The company has approximately 30 projects in the screening stage, targeting areas such as oncology, autoimmune, respiratory, and ophthalmology[47] Market and Sales Performance - The company's innovative drug, Ciprofol Injection, achieved sales revenue of approximately 340 million yuan in the first half of 2023, with a market share increase from 2.33% in Q1 2022 to 8.39% in Q1 2023[17] - Dolasetron Mesylate Injection (Libifu) maintained a market share of around 8% in H1 2023, with a smooth transition from agency to direct sales model[17] - Polyene Phosphatidylcholine Injection (Sifu) saw a market share increase to 10.8% in April-May 2023, up 31.6% from the previous period, covering 4,274 hospital terminals[17] - Methylprednisolone Sodium Succinate for Injection (Siwu) held a 42.68% market share in systemic glucocorticoids in 2022, with Siwu accounting for 8.2% of the Methylprednisolone Injection market, growing by 80.3%[18] - Flupentixol and Melitracen Tablets (Lepan) captured a 4.15% market share in 2022, ranking third in its product category[18] - The company's marketing center achieved its goals, with the market share of innovative drugs increasing, and the sales of ciprofol injection reaching a record high of 900,000 units in June 2023[30] - Total operating revenue increased by 9.81% YoY to RMB 1,369,698,088.21, with the pharmaceutical industry contributing 99.33% of the revenue[50] - Anesthesia products revenue surged by 165.71% YoY to RMB 342,656,667.79, accounting for 25.02% of total revenue[50] - Revenue from the Eastern region grew by 37.89% YoY to RMB 200,319,254.36, while the Western region declined by 6.19% YoY to RMB 451,912,919.29[50] - The company's gross margin for the pharmaceutical industry improved by 2.19% YoY to 71.54%[52] Production and Operations - The company's production model is mainly self-production, supplemented by cooperative production, with four production bases in Liaoning and Sichuan[21] - The company's marketing system includes a professional academic promotion model and a full-channel marketing model, covering both in-hospital and out-of-hospital channels[20] - The company's production capacity is supplemented by a new production base in Shannan, Tibet[21] - The company's total production of formulations and APIs increased by 18% year-over-year, with 3,730 million bottles/bags produced in Liaoning and 13,010.39 million tablets/capsules produced in Meishan[32][34] - The company invested RMB 956,392.66 in the construction of the Tibet Pharmaceutical Factory during the reporting period, with a cumulative investment of RMB 67,714,549.77 and a project progress of 99%[60] - The company's financial assets at the end of the period totaled RMB 240,932,227.19, with a decrease of RMB 236,191,488.32 due to factors such as the recovery of principal from wealth management products and a reduction in receivables financing[56] - The company's other equity instrument investments decreased by RMB 3,441,551.35, resulting in a final balance of RMB 212,053,410.19[56] - The company's receivables financing decreased by RMB 32,749,936.97, with a final balance of RMB 28,878,817.00[56] - The company's investment in Hicreative Pharmaceuticals (stock code: 688302) had an initial cost of RMB 33,811,556.98 and a final book value of RMB 108,602,565.12[62] - The company raised RMB 790,866,217.58 through a non-public stock issuance in 2023, with RMB 514,450,400 used during the reporting period and RMB 278,170,200 remaining unused[64] - The company's fundraising account balance as of June 30, 2023, was RMB 198,170,181.87[64] - The total balance of the company's raised funds as of June 30, 2023, is RMB 198,170,181.87, distributed across multiple bank accounts[65] - The company has pre-invested RMB 307,221,893.63 of self-raised funds into the raised funds projects and partial issuance expenses, which will be replaced by raised funds[65] - The company has temporarily supplemented its working capital with RMB 80 million from idle raised funds, with a maximum limit of RMB 200 million approved for this purpose[65] - The company has used idle raised funds for cash management, achieving a cumulative cash income of RMB 2,103,720.16 during the reporting period[65] - The investment progress of the long-acting oral hypoglycemic drug HSK7653's Phase III clinical research and registration project in China is 35.50%, with RMB 14,024.85 invested in the current period[67] - The investment progress of the new peripheral neuropathic pain treatment drug HSK-16149 capsule's Phase II/III clinical research and registration project in China is 100.00%, with RMB 12,406.66 invested in the current period[67] - The investment progress of the post-marketing re-evaluation project of Acetyl-L-Carnitine Hydrochloride Tablets in China is 70.97%, with RMB 4,013.53 invested in the current period[67] - The investment progress of the supplementary working capital and bank loan repayment project is 85.71%, with RMB 21,000 invested in the current period[67] - Total funds raised amounted to 82,073.71 million RMB, with 51,445.04 million RMB already utilized[68] - The company used 307,221,893.63 RMB of self

表决结果：7 票同意、0 票弃权、0 票反对 详见公司同日刊登于巨潮资讯网等公司指定信息披露媒体的《公 司 2023 年半年度报告及摘要》。 二、审议通过了《关于会计政策变更的议案》 证券代码：002653 证券简称：海思科 公告编号：2023-100 海思科医药集团股份有限公司 第四届董事会第五十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）第四届董事 会第五十四次会议（以下简称"会议"）于 2023 年 8 月 16 日以通讯 表决方式召开。会议通知于 2023 年 8 月 4 日以传真或电子邮件方式 送达。会议由公司董事长王俊民先生召集并主持。会议应出席董事 7 人，以通讯表决方式出席董事 7 人。本次会议的通知、召开以及参与 表决董事人数均符合有关法律、法规、规则及《公司章程》的有关规 定。全体董事经过审议，以投票表决方式通过了如下决议： 一、审议通过了《公司 2023 年半年度报告及摘要》 表决结果：7 票同意、0 票弃权、0 票反对 董事会认为：本次会计政策变更是根据财政部颁布的相关 ...

证券代码：002653 证券简称：海思科 公告编号：2023-103 海思科医药集团股份有限公司 海思科医药集团股份有限公司（下称"公司"）于 2023 年 8 月 16 日召开的第四届董事会第五十四次会议审议通过了《关于会计政 策变更的议案》。本次会计政策变更无需提交股东大会审议。现将有 关情况公告如下： 一、本次会计政策变更情况概述 （一）2022 年 11 月 30 日，财政部发布了《企业会计准则解释 第 16 号》（财会〔2022〕31 号）（以下简称"准则解释第 16 号"）， 规定"关于单项交易产生的资产和负债相关的递延所得税不适用初始 确认豁免的会计处理"的内容自 2023 年 1 月 1 日起施行；"关于发 行方分类为权益工具的金融工具相关股利的所得税影响的会计处理" 及"关于企业将以现金结算的股份支付修改为以权益结算的股份支付 的会计处理"的内容，自公布之日起执行。公司根据上述要求对会计 政策相关内容进行相应变更。 （二）变更前后采用的会计政策 1 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据《准则解释第 16 ...